CLL Associated studies

 Open trials

Short name M18-803 T-PLL
Study title A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-Cell Prolymphocytic Leukemia
Reference NCT03873493
Status Open
Participants M. Bellido, Universitair Medisch Centrum, Groningen;
L. Tick, Maxima Medisch Centrum, Eindhoven;
Study docs Eligibility criteria
Short name ACE-CL-311
Study title A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation.
Reference NCT04008706
Status Open
Participants AmsterdamUMC - location AMC – Arnon Kater
Flevoziekenhuis – Koen de Heer
Study docs Flow + Eligibility criteria
Short name ACE-CL-312
Study title A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
Reference NCT04008706
Status Open only for patients with prior BTKi therapy (Cohort3) (Other cohorts: Treatment-naive patients and enrollment of patients with Relapsed/Refractory disease are complete)
Participants Open in:
Universitair Medisch Centrum Utrecht (Utrecht) Rogier Mous (
Will also be opened in:
Albert Schweitzer Ziekenhuis (Dordrecht), Mark-David Levin
HagaZiekenhuis (Den Haag), Sabina Kersting
Rijnstate Ziekenhuis (Arnhem) Ellen vd Spek
Isala Klinieken (Zwolle), Ellen Dompeling
Study docs Flow + Eligibility criteria